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Abstract 
Problem statement and background 
More than 250,000-500,000 bloodstream infections due to intravascular devices occur 
each year in the United States.  With a mortality rate between 12% and 25%, these infections 
have become a focus of healthcare research.  A single bloodstream infection (BSI) can cost 
$36,000-$107,000, with an average annual cost up to $28 billion. Most studies concerning BSIs 
involve central line access, however, the limited number of studies that have investigated 
peripheral IV’s association with BSI’s have found an infection rate of 0.5 per 1000 catheter days 
versus 2.7 for central line catheters.  A systematic review and subsequent research 
demonstrated that use of alcohol impregnated port protectors reduced the number of central line 
associated bloodstream infections (CLABSIs).   
Purpose and research questions 
To examine the cost effectiveness of using alcohol impregnated caps on peripheral IVs 
to prevent BSIs.   
Conclusions—Recommendations for practice 
 There is a lack of research involving the use of port protector caps on peripheral 
intravenous lines.  However, evidence demonstrates that BSI’s from peripheral IV’s do occur 
and can cost hospitals billions each year.  Approximately 25 million patients receive peripheral 
IVs in US hospitals each year.  The annual cost of utilizing 10 port protectors per peripheral IV 
started would cost $72.5 million. US hospitals would comparatively spend a minimum of $450 
million to treat peripheral IV associated BSIs.  Based on the available research there is 
evidence that universal policies for the use of alcohol impregnated port protector caps on 
peripheral IVs, as well as CVCs, would not only improve patient outcomes but be financially 
beneficial to the hospitals.  It is recommended that a research study examine the use of alcohol 
impregnated caps on peripheral IVs and the subsequent effect on BSI incidence and hospital 
cost. 
